Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc is progressing positively in its clinical trials, particularly with BX211 for diabetic foot osteomyelitis (DFO), where favorable trends in clinical parameters were observed, including a higher proportion of visits with no infection evidence and demonstrated improvements on the Wagner scale. Additionally, BiomX has received encouraging feedback from the FDA to advance its BX011 multi-phage cocktail into Phase 2a studies focusing on critical efficacy endpoints, which suggests a strong regulatory outlook. The company's strategic plans to expand market penetration, pursue additional indications, and explore international opportunities further enhance its growth potential, positioning BiomX favorably within the biopharmaceutical sector.

Bears say

BiomX Inc. is currently facing significant challenges that contribute to a negative outlook regarding its stock performance, primarily stemming from clinical trial results that did not fully meet conventional statistical significance thresholds. The company's reliance on successful clinical outcomes and the need for adequate funding to advance its drug development are critical concerns, as any failures or inconclusive results in trials could severely impact investor confidence and financial stability. Additionally, potential risks associated with dilutive capital raises and a lack of commercial success further amplify uncertainties surrounding BiomX's future growth and market viability.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.